Clinical Trial Update: Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating simvastatin as an inhibitor of cell adhesion–mediated drug resistance in patients with refractory multiple myeloma; the study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED